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j Abstract Background Neurasthenia has had a
chequered history, receiving changing labels such as
chronic fatigue or Gulf war syndrome. Neurasthenia is
recognized by ICD-10, but not by DSM-IV. Its course,
longitudinal stability and relationship to depression is
not well understood. Methods In a stratified com-
munity sample (n = 591), representative of 2600
persons of the canton of Zurich, Switzerland, neur-
asthenia and depression were assessed in six struc-
tured interviews between ages 20 and 41. Course,
stability and comorbidity were examined. A severity
spectrum of neurasthenia and depression from
symptoms to diagnosis was taken into account. Re-
sults The annual prevalence of a neurasthenia diag-
nosis increased from 0.7% to 3.8% from age 22–41,
while mere symptoms became less prevalent. Intra-
individual courses improved in 40% and deteriorated
in about 30% of symptomatic cases. The most fre-
quent symptoms overall, besides criterial exhaustion,
were increased need for sleep, over-sensitivity, ner-
vousness and difficulty concentrating. Cross-sectional
associations and overlap with depression were strong.
Longitudinal stability of ICD-neurasthenia was low.
Conclusions Neurasthenia is intermittent, overlaps
significantly with depression, and shows improve-
ment and deterioration over time to roughly equal
measures.
j Key words neurasthenia Æ depression Æ prevalence
Æ course Æ comorbidity Æ spectrum
Introduction
Neurasthenia is operationally defined by ICD-10 [39]
as a syndrome of mental fatigue and/or physical
exhaustion with a minimum duration of 3 months. Its
world-wide significance was definitely established by
the large prospective transcultural study of the WHO
in general health care [25, 32]. In the United States it
is dealt with mainly as the neurological disorder
chronic fatigue syndrome (see review by Wessely
[37]) and is absent from the psychiatric classification
of DSM-IV (discussed by Morey and Kurtz [22]).
The history of neurasthenia has been summarised
by Steiner [30], Fischer-Homberger [14], Gosling [16],
Shorter [29], Wessely [36], Taylor [31] and Scha¨fer
[26, 27]. According to Scha¨fer [26], neurasthenia was
an element of melancholia until the 17th century. In
the 18th century it was regarded as an element of
hypochondriasis, and became an independent neu-
ropsychiatric syndrome with Beard [8] and Van
Deusen [33]. Over the past two decades it has con-
tinued to change its labels in a chameleon-like fashion
in order to be socially acceptable and not stigmatis-
ing, overlapping with chronic fatigue syndrome,
myalgic encephalomyelitis [36], Gulf War syndrome
[18], burn-out syndrome [15], as well as with atypical
depression [6].
Most research has focussed on chronic fatigue, and
its symptoms have been studied internationally [38].
But it is plausible that a large number of patients also
suffer from acute, shorter and impairing fatigue
syndromes, as shown by earlier reports from the
Zurich Study [1, 7, 21]. Such a dimensional neuras-
thenia spectrum was also proposed early by Sharpe
et al. [28] and Pawlikowska et al. [23].
In the Zurich Study of a community sample the
neurasthenic syndrome was one of 30 psychological
and functional somatic syndromes assessed in six
interviews from the ages of 20–41 [3]. The data make
it possible to analyse symptoms of neurasthenia on aEA
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continuum from tiredness to severe physical and
mental fatigue and exhaustion (neurasthenia spec-
trum), its longitudinal development over 20 years and
its association with depression.
Methods
j Sample
The initial Zurich Study sample consisted of 4547 subjects (2201
men, 2346 women) representative of the canton of Zurich in
Switzerland, who were screened with the Symptom Checklist 90-R
(SCL-90-R; (17)). In order to increase the probability of including
individuals at risk for psychiatric syndromes, a stratified subsample
of 591 subjects (292 males, 299 females) was selected for interview,
with 66% comprising individuals who scored above the 85th per-
centile on the SCL-90-R Global Severity Index (‘high-risk group’),
and 33% comprising a random sample of those scoring below the
85th percentile (‘low-risk group’). The 591 subjects are represen-
tative of 2600 persons from the canton of Zurich. The initial
screening was conducted in 1978, when the subjects were aged 19
(men) and 20 (women). Full interviews were conducted in 1979,
1981, 1986, 1988, 1993, and 1999, by trained clinical psychologists
or psychiatrists in the participants’ homes. A broad spectrum of 30
psychiatric and somatic syndromes was assessed, including
exhaustion/fatigue and depression [3]. The interviewers all had a
degree in psychopathology. They were trained in group interviews
and by learning from experienced interviewers during interviews in
the participants’ homes.
j Neurasthenia interview
The stem questions were adapted to current ICD concepts of
neurasthenia and were in 1993/1999: 1) ‘‘in the last 12 months, did
you experience being physically exhausted, washed out, done in,
shattered, even in situations of marginal physical effort?’’, and 2)
‘‘in the last 12 months, did you sometimes experience a pro-
nounced mental exhaustion and fatigue, even in situations of
marginal mental effort?’’ If one of the questions was answered with
yes, 20 symptoms were checked and an open question asked for
possible other symptoms; the symptoms are listed in Table 2 of the
results section.
j Validity and reliability of interview
While we do not have data on the reliability of the interview section
on neurasthenia, we have such data for the section on depression,
which includes the ‘‘neurasthenic’’ items fatigue, lack of energy and
motor slowing. In 1993, at the 5th interview of the Zurich study, an
interrater-reliability analysis was conducted in eight raters who
rated 22 participants using the depression section of the SPIKE
interview. The percent interrater agreement on the presence/ab-
sence of symptoms was 95.6%. The corresponding mean value of
Kappa was 0.89, indicating almost perfect agreement [5].
In 1984, after the 2nd interview, the sensitivity of the stem
question for depression was calculated in 90 outpatients, against
two gold standards: (1) the presence/absence of an ICD diagnosis
for depression in the patient’s medical history, and (2) the patient’s
BDI score, with scores >7 indicating depression [20]. Sensitivity
was 0.93 in the first, and 0.98 in the second case. Since the answer to
the stem question decides on who will be questioned further on the
particular syndrome, these sensitivies indicate that the SPIKE stem
question captured almost all patients who had a confirmed diag-
nosis of depression.
Taken together, we conclude that the SPIKE section on
depression picks up the large majority of subjects at risk for
depression, and that the assessment of these subjects’ symptoms by
the interviewers was reliable and consistent. We cannot answer the
question for the neurasthenia section of the interview, but given the
results for depression, we have no reason to doubt the reliability of
the assessment of neurasthenic symptoms by our interviewers.
j Diagnoses
Neurasthenia was defined by ICD-10 criteria [39] as a syndrome of
mental fatigue and/or physical exhaustion with at least one of six
criterial symptoms and a minimum duration of 3 months. No
exclusion criteria were applied in order to allow us to study the
associations with other syndromes. In the first interview (1979) 3-
months neurasthenia was not yet assessed, only 1-month neuras-
thenia and shorter manifestations.
No somatic examinations were conducted to ascertain potential
somatic causes of neurasthenia. Only attributions of somatic causes
by the participants were recorded, which are known not to be a
reliable guide to the presence of objective somatic causes. Inspec-
tion of the somatic causes reported by the subjects identified
roughly three subjects per interview who might qualify for an or-
ganic cause for neurasthenic manifestations. None of these causes
belonged to those listed in the ICD’s exclusion criteria. Due to their
small number and to the unreliability of causal attributions we did
not exclude these subjects from analysis.
Our neurasthenic spectrum consists of: (1) 3-months neuras-
thenia according to ICD-10, (2) 2-weeks neurasthenia [7], (3)
recurrent brief neurasthenia (RBN) [1] and (4) neurasthenic
symptoms. RBN required the presence of a neurasthenic syndrome
of short duration (<2 weeks) occurring at least 12 times in the
previous year. Our spectrum concept arose from the systematically
collected data in all syndromal sections of the interview; after the
stem questions and list of symptoms, the duration (maximum,
average) and frequency of neurasthenic episodes were assessed for
the last 12 months as well as the estimated number of days/year
with neurasthenic symptoms. Neurasthenia subgroups were formed
according to different duration, frequency and severity criteria and
the resulting spectrum was validated using clinical indicators such
as treatment and suicide attempt rates, comorbidity, work and
social impairment [2, 7, 21].
Major depressive episodes (MDE) were defined according to
DSM-III R and dysthymia according to DSM-IV, without the
application of any exclusion criteria. Our definition of minor
depression was strict, i.e. requiring not two but three to four of the
nine criterial symptoms of depression and a duration of at least
2 weeks. Recurrent brief depression was defined by about monthly
or more frequent episodes of depression lasting <2 weeks, by the
presence of five or more of the nine criterial symptoms, plus work
impairment (ICD-10).
The diagnosis of bipolar I disorder was similar to the original
definition of Dunner et al. [12], i.e. the presence of mania requiring
hospitalisation was necessary; bipolar II disorder required the
presence of a major depressive episode (DSM-III R) and episodes of
overactivity plus two of seven criterial hypomanic symptoms [4]. A
diagnostic group of minor bipolar disorder (MinBP) was included
in the bipolar spectrum concept, comprising dysthymia, minor and
recurrent brief depression in association with two of seven criterial
hypomanic symptoms, and the chronic form, cyclothymic disorder
[4].
j Statistics
Prevalence rates were corrected for stratified sampling and
weighted back to the population of 2600 subjects. We sometimes
report ‘‘cumulative prevalence’’ rates, which is the prevalence
cumulated over six interview years, i.e. the prevalence of ever
having had a given syndrome/symptom in the 12 months preceding
any of the interviews. Frequencies were compared across groups
using v2-tests; Kruskal-Wallis tests were used for continuous data.
For the analysis of symptom frequency (Table 2), in which several
independent tests were carried out, we indicate which tests would
be significant after Bonferroni correction.
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To assess the longitudinal relationship between neurasthenia
and depression, we ran a number of regression models. First,
generalized estimating equations (GEE) models with dichotomous
dependent and independent variables were run. GEE models in-
clude the data from all time points of a longitudinal study. Our
first model included 3-months neurasthenia as the dependent
variable; the predictor variables were: 3-months neurasthenia at
any previous interview, a major depressive episode (MDE) at the
same interview, and MDE at any previous interview. A second
model included MDE as the dependent variable and the predic-
tors were: 3-months neurasthenia at the same interview, 3-
months neurasthenia at any previous interview, and MDE at any
previous interview.
Variants of the two models were computed by replacing the
predictor variables referring to any previous interview with pre-
dictors referring only to the preceding interview (1st-order lag
variables). Sex, risk group and time were additional predictors in
all GEE models.
As a simple test for the adequacy of the models, we compared
the results of running these models with and without requiring
robust Standard Errors, and found very good agreement, i.e. no
more than 10% difference in SEs, and identical patterns of statis-
tical significance.
The GEE models accommodate the longitudinal dependence
of observations by directly modeling the within-subject correla-
tion structure of the data. In this case, we chose an independent
correlation structure that assumes independent correlations of
observations within a single individual between adjacent points
in time, as recommended by Diggle et al. [11] for transition
models.
Results
j Frequency and prevalence of diagnostic sub-groups
Table 1 shows that there was an increase of the one-
year prevalence of 3-months neurasthenia from 0.7%
to 3.8% from the second to the sixth interview (ages
22–41 years), and a decrease in the group with
neurasthenic symptoms. RBN did not change clearly
(from 5.4% to 4.7%), whereas 2-weeks neurasthenia
increased from 2.4% to 7.4%. Across 20 years the
cumulative incidence rate of 3-months neurasthenia
was 6.0%, 5.5% for men and 6.5% for women (gender
ratio F:M = 1:2:1). Restricted to cases with work and/
or social impairment the cumulative incidence rate of
3-months neurasthenia remained 5.6%. The preva-
lence rate of treated 3-months neurasthenia was 3.2%,
which represents 53.1% of all cases.
j Stem questions
The two stem questions of criterion A of ICD-10
(physical and mental exhaustion/fatigue) were as-
sessed separately in 1993 and 1999. Women com-
plained of suffering from both symptoms slightly
more often than men (prevalence rates 14.7% vs.
10.3%; P = 0.32); they reported physical exhaustion
twice as often as men (16.5% vs. 7.9%; P = 0.007),
whereas mental exhaustion was reported to a similar
extent by women and men (10.2% vs. 9.1%;
P < 0.77).
j Symptoms
About 20 symptoms of neurasthenia, assessed during
the third to the sixth interview (age 28–41), are listed
in Table 2 for four groups: 3-months neurasthenia, 2-
weeks neurasthenia, RBN and neurasthenic symp-
toms. 3-months neurasthenia generally had the
highest load of symptoms, whereas subjects with only
neurasthenic symptoms had the smallest load. The
profiles of RBN and 2-weeks neurasthenia were
roughly similar.
Apart from the characteristic symptoms of physical
and mental exhaustion with increased need for sleep,
the most frequent symptoms were over-sensitivity to
external stimuli and to critical remarks, tension and
difficulty concentrating. Over-sensitivity was also
accompanied by lower stress tolerance.
j Longitudinal overlap between neurasthenia and
depression
The longitudinal overlap was strong. Fourty-four
(68.5%) of the 64 subjects who ever reported 3-
months neurasthenia in any of the interviews also
ever reported MDE (OR = 4.5, 95% C.I. 2.5–7.9,
P < 0.001; Fig. 1). Sixty to 79% of the subjects with
3-months neurasthenia had a previous or sub-
sequent episode of subthreshold or threshold mood
disorder. Twelve (18.8%) of the 64 cases with 3-
months neurasthenia overlapped with dysthymia,
minor depression or recurrent brief depression. 3-
months neurasthenia without anxiety (panic or
GAD) or mood disorder occurred in only 1.4% of
the sample. Thirty-seven (55.2%) of the 67 subjects
who ever suffered from 2-weeks neurasthenia ever
had MDE (OR = 3.3, 95% C.I. 2.0–5.4, P < 0.001). If
we include all subjects who ever reported symptoms,
316 (82.7%) of the 382 who ever reported neuras-
thenic symptoms also at some time reported
depressive symptoms (OR = 6.9, 95% C.I. 3.6–13.5,
P < 0.001).
Table 1 One-year and cumulated one-year prevalences (95% confidence
intervals) of subgroups of neurasthenia across six interviews
Age (m/f) Symptoms RBN 2-weeks 3-months
20/21 24.6 5.4 2.4
(19.9–30.1) (3.3–8.8) (1.2–4.9) –
22/23 19.1 1.9 0.9 0.7
(14.5–24.9) (1.0–3.5) (0.2–3.2) (0.2–3.4)
27/28 7.1 4.8 1.8 1.3
(4.4–11.4) (2.6–8.5) (0.7–4.5) (0.5–3.3)
29/30 8.1 3.1 3.0 3.0
(5.0–12.8) (1.5–6.2) (1.3–6.7) (1.4–6.1)
34/35 6.8 4.0 1.0 2.0
(4.0–11.6) (2.0–7.9) (0.3–3.6) (0.8–4.9)
40/41 5.8 4.7 7.4 3.8
(3.1–10.5) (2.4–8.8) (4.3–12.5) (1.8–7.7)
Cumulative 28.4 12.1 9.7 6.0
(23.3–34.1) (8.8–16.3) (6.7–13.8) (3.9–9.2)
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j Age and order of onset
Overall the age of onset of neurasthenic symptoms
was 20.1 ± 6.9 years; the four groups of neurasthe-
nia did not differ significantly in this respect
(P < 0.34). The onset of depressive symptoms oc-
curred on average four years earlier (15.9 ± 5.8
years). In 99 cases (18.3%), the age of onset of
neurasthenic and depressive symptoms was the
same (including an error margin of ±1 year), in 237
cases (43.7%) depression preceded neurasthenia, in
71 cases (13.1%) neurasthenia preceded depression,
while another 121 cases (22.3%) suffered only from
depression and 14 cases (2.6%) only from neuras-
thenia.
j Course of diagnostic subgroups: changes on the
severity spectrum
We compared each subject’s first and last completed
interview (the first being for all subjects the one
completed at age 20, the last varying according to the
subject). 105 (27.3%) of all subjects who had ever
experienced any kind of neurasthenic manifestations
stayed in the same diagnostic subgroup, i.e. there was
no change in severity of the manifestation. 124 sub-
jects (32.3%) switched to a more severe subgroup
between their first and last interviews and 155 (40.4%)
to a less severe subgroup.
In a more fine-grained analysis, we investigated
the change of neurasthenia subgroup between the
first and last completed interview, quantifying the
change in terms of units, with one unit corre-
sponding to one step up to the next, more severe,
subgroup of neurasthenia or down to the next, less
severe, subgroup. Subgroups in order of ascending
severity were ‘‘no neurasthenia’’, ‘‘neurasthenia
symptoms’’, ‘‘recurrent brief neurasthenia’’, ‘‘two-
week neurasthenia’’, and ‘‘3-month neurasthenia’’.
For example, a subject who changed from recurrent
brief neurasthenia at the first interview to 3-months
neurasthenia at the last interview would be assigned
a change in severity of +2. Figure 2 shows the
histogram of severity changes. It is evident that by
far the most frequent classes were those subjects
who stayed in their neurasthenia subgroup, and
those who changed to the next lower (less severe)
subgroup. While overall, more subjects got better
than worse, considerably more ‘‘jumped’’ up two or
20 44 1483-months
neurasthenia
MDE
66 316 157Neurasthenia
symptoms
Depressive
symptoms
Fig. 1 Longitudinal overlap of neurasthenia and depression
Table 2 Frequency of symptoms of
neurasthenia in different subgroups Neurasthenia
Groups 1 2 3 4 p (1–4) p (2–4)
Diagnosis Symptoms RBN 2-weeks 3-months
Subjects 68 69 47 63
Symptoms % % % %
1 Low energy 10.3 30.4 23.4 39.7 0.02 0.04
2 Exhaustion 80.9 88.4 89.4 92.1 0.25 0.002
3 Physical weakness 52.9 60.9 74.5 74.6 0.03 0.002
4 Excessive physical fatigue 52.9 60.9 74.5 81.0 0.004 0.0001*
5 Excessive mental fatigue 52.9 60.9 44.7 47.6 0.04 0.05
6 Fatigue after marginal physical effort 52.9 60.9 47.5 81.0 0.004 0.0001*
7 Increased need for sleep 58.8 85.2 87.2 92.1 0.0001* 0.0001*
8 Disturbed sleep 14.7 30.4 23.4 36.5 0.03 0.07
9 Oversensitive to external stimuli (noise, light) 61.8 73.9 61.7 76.2 0.17 0.09
10 Oversensitive to critical remarks 55.9 71.0 74.5 81.0 0.02 0.007
11 Tense, irritable 72.1 92.8 85.1 85.7 0.01 0.18
12 Unable to relax 17.4 34.8 31.9 46.0 0.007 0.03
13 Muscle pain or heavy limbs 39.7 59.4 36.2 52.4 0.04 0.30
14 Difficulty concentrating 61.8 79.1 61.7 74.6 0.06 0.52
15 Easily distracted 23.5 40.6 46.8 41.3 0.05 0.27
16 Difficulty thinking/memory problems 48.5 73.9 44.6 63.5 0.004 0.09
17 General performance impaired 41.2 49.3 59.6 61.9 0.08 0.007
18 Diminished need for social contacts 8.8 21.7 21.3 30.2 0.03 0.12
19 Less able to withstand stress 58.8 71.0 70.2 77.8 0.13 0.03
20 Sensitive to weather 19.1 30.4 40.4 34.9 0.08 0.54
* Significant after Bonferroni correction (40 tests)
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more subgroups than ‘‘jumped’’ down two or more
subgroups.
j Transitions between and diagnostic stability of
subgroups of neurasthenia
We first analysed the intra-individual diagnostic sta-
bility of neurasthenia across all interviews, merging
the interviews at t1 and t2 (age 21 and 23) as well as
those at t3 and t4 (age 28 and 30) and comparing them
with t5 (age 35) and t6 (age 41). In general, none of the
subgroups of neurasthenia showed high longitudinal
stability (Fig. 3). On average, only about 15% of the
subjects remained in their subgroup across two
adjacent time points. A similar proportion changed to
other subgroups of neurasthenia. Most subjects in any
subgroup, however, changed to the symptom-free
group at the next time point.
In addition, we examined the history and follow-up
of the individually last and first episodes of 3-months
neurasthenia, respectively. Cumulatively, all changes
across the interviews were taken into account, not just
the first and last interview as in section 3.6 (for more
details, see legend to Fig. 4). Figure 4 shows subgroup
changes from and to 3-months neurasthenia. The
stability of 3-months neurasthenia was low: the first
episode was followed by the same diagnosis in only
23% of cases, and only 16% of last observed episodes
had a history of a previous episode. Over 75% of
subjects with 3-months neurasthenia had a previous
or subsequent symptom-free period. Combining 3-
months and 2-weeks neurasthenia into one group
resulted, as expected, in a slightly higher stability: in
this case one fourth of the subjects ever had a previ-
ous, and one third ever had a subsequent episode of
neurasthenia. GEE confirmed the low stability of 3-
months neurasthenia: the OR of prediction of current
by previous neurasthenia was non-significant.
j GEE models of associations between 3-months
neurasthenia and MDE
In the ‘‘cumulative exposure’’ GEE model (Table 3a),
3-months neurasthenia was predicted neither by a
previous diagnosis of 3-months neurasthenia, nor by
a previous diagnosis of MDE. It was, however,
strongly associated with concurrent MDE. MDE was
predicted by previous diagnoses of MDE and 3-
months neurasthenia, and was also strongly related to
concurrent 3-months neurasthenia.
The first-order lag model (Table 3b) differed from
the cumulative exposure model in that MDE in the
previous interview predicted 3-months neurasthenia,
while 3-months neurasthenia in the preceding inter-
view did not predict current MDE. Thus, whereas
cumulative previous exposure to MDE did not predict
current 3-months neurasthenia, exposure in the pre-
ceding interview did. Furthermore, whereas cumula-
tive previous exposure to 3-months neurasthenia
predicted current MDE, exposure in the preceding
interview did not.
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first and last completed interview. One unit corresponds to a change into the
next higher or lower subgroup. See text for further explanation
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ageFig. 3 Temporal shifts between subgroups of
neurasthenia between two successive time points.
An example for how to read this figure: at ages 21–
23, 181 particpants reported neurasthenic symptoms
(‘‘Neur sx’’), and of these, 56% became symptom-
free (‘‘No sx’’) at ages 28–30. This can readily be
seen by following the uppermost line originating
from the box reading ‘‘181’’. ‘‘No sx’’ = no
neurasthenic symptoms, ‘‘Neur sx’’ = neurasthenic
symptoms. ‘‘RBN’’ = Recurrent Brief Neurasthenia.
‘‘2-w Neur’’ = 2-weeks neursthenia, ‘‘3-m
Neur’’ = 3-months neurasthenia (ICD-10)
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Female sex increased the risk for neurasthenia and
for MDE in the first order lag model. The risk group
for stratified sampling was significant, indicating that
high-risk status entailed a higher risk for neurasthe-
nia and depression. Time was not a clinically signifi-
cant predictor (ORs close to 1).
Discussion
This paper presents prospective data on the course
and diagnostic stability of neurasthenic syndromes/
symptoms across 20 years and their associations with
depressive syndromes/symptoms.
j Symptoms
Among cases of 3-months neurasthenia two major
syndromes could be found, the typical fatigue syn-
drome (exhaustion, weakness, increased need for
sleep) and a syndrome of reduced stress tolerance
(including oversensitivity to external stimuli and to
critical remarks, tension and irritability). Together
they correspond to the original concept of ‘‘excessive
irritable weakness’’ of [9].
j Prevalence
Three-months neurasthenia was clearly age-related:
from age 22 to 41 there was a systematic several-fold
increase of the one-year prevalence of 3-months
Table 3 GEE models of neurasthenia and depression: odds ratios
Dependent variable Explanatory variables
3-months neurasthenia
(ICD-10)
MDE Male Risk Time
Previousa Samea Previous Same
a. Cumulative exposure model
3-months neurasthenia (ICD-10) 1.8 – 1.1 6.4*** 0.5* 2.3* 1.0
MDE 2.0* 6.4*** 2.0*** – 0.9 1.7** 0.98
b. First-order lag model
3-months neurasthenia (ICD-10) 1.3 – 1.9* 5.9*** 0.5** 2.2* 1.1**
MDE 1.5 5.8*** 2.1*** – 0.7* 1.9*** 1.0
a ‘previous’ indicates presence of explanatory variable at any previous interview (cumulative exposure); ‘same’ indicates presence of explanatory variable at same
interview
b ‘–’ indicates explanatory variable not included in model
***P < 0.001, **P < 0.01, *P < 0.05
a ‘previous’ indicates presence of explanatory variable at the preceding interview (first-order lag); ‘same’ indicates presence of explanatory variable at same interview
b ‘–’ indicates explanatory variable not included in model
***P < 0.001, **P < 0.01, *P < 0.05
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3-months
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asthenia
2-w neur
UP/BP Dx
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UP/BP Dx
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3-m neur
No sxNo sx
N=64N=43
Follow-back of last episodeFollow-up of first episode
27%
17%
16%
81%
52%
26%
19%
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77%
Fig. 4 Follow-up of the first and follow-back of the last episode of 3-months
neurasthenia. The first and last episode of 3-m neurasthenia is identified in
each subject (these episodes can be in different years for different subjects).
The right side of the figure shows the percentages of subjects with a last
episode of 3-month neurasthenia belonging to any of the listed subgroups in
any previous interview. Percentages do not sum to 100% because the
subgroups are not mutually exclusive: A subject may have belonged to more
than one subgroup prior to the last episode of 3-months neurasthenia.
Analogous considerations hold for the left side of the figure, which shows the
percentages of subjects with a first episode of 3-months neurasthenia
belonging to any of the listed subgroups in any subsequent interview. ‘‘3-m
neur’’ = 3-months neurasthenia, ‘‘2-w neur’’ = 2-weeks neurasthenia, ‘‘UP/BP
Dx’’ = uni- or bipolar mood disorder, ‘‘UP/BP SubDX’’ = uni- or bipolar
subthreshold mood disorder, ‘‘No sx’’ = no neurasthenic symtpoms
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neurasthenia, while neurasthenic symptoms prevailed
at age 20–22 and decreased thereafter. A representative
twin study of adolescents found a lifetime prevalence
of neurasthenia of 2.3%, which is compatible with our
assumption of an increase with age [13]. Cumulatively
up to age 41, we found 6.0% 3-months neurasthenia.
j Gender differences
Women reported physical exhaustion twice as often
as men, whereas mental exhaustion was reported to a
similar extent by women and men. Nonetheless, the
prevalence of 3-months neurasthenia was only slightly
higher for women than for men (gender ratio
F:M = 1:2:1, whereas it was about 2:1 in the study of
Farmer et al. 2004). In this context our findings on
atypical depression are of interest, because there we
found a clear preponderance of women with a
cumulative prevalence rate of 6.3% for women versus
1.6% for men (ratio F:M = 3:9:1), explaining the
gender difference in prevalence rates for major
depressive episodes [6]. These results also illustrate
that the two syndromes, neurasthenia and atypical
depression, differ substantially although they share
certain diagnostic symptoms.
j Course of neurasthenic spectrum
Overall, there was a moderate decrease in severity of
neurasthenic manifestations from the first to the last
individual interview: 27% of the subjects stayed the
same, 40% got better and 32% got worse. Analysis of
temporal shifts revealed that the increase of 3-months
neurasthenia with age was not generally at the cost of
neurasthenic symptoms, since most cases with neur-
asthenic symptoms became symptom-free, and only a
total of 13% ever changed to 3-months neurasthenia
(data not shown).
A main finding is that neurasthenia, in contrast to
depression, was a rather unstable diagnosis. For each
point in time, the majority of cases with any neuras-
thenic manifestation switched to the symptom-free
group at the next interview. In the GEE model, pre-
vious 3-months neurasthenia did not predict sub-
sequent 3-months neurasthenia.
j The cross-sectional and longitudinal association of
neurasthenia and depression
The cross-sectional association of neurasthenia with
depression is well-established [10, 13, 17, 19, 22, 24,
34, 35, 37]. In cases of co-occurrence the diagnosis of
depression often took precedence over that of neur-
asthenia [25]. In our data cross-sectional associations
between neurasthenia and depression were strong and
statistically significant. Longitudinally, previous
depressive states on all diagnostic levels consistently
predicted subsequent depression whereas, as we have
seen, neurasthenic syndromes were temporally
unstable. The prediction of 3-months neurasthenia by
MDE and vice versa was weak and inconsistent be-
tween the two GEE models.
j Limitations
With fatigue being an ubiquitous and unspecific
symptom of many illnesses, the question of etiological
heterogenetiy becomes particularly relevant. In par-
ticular, a fatigue syndrome due to a somatic illness or an
accident may have a different etiology than ‘‘non-or-
ganic’’ neurasthenia. But then again, it may not. Fatigue
may have a proximal cause that is the same or very
similar everywhere it occurs, and different illnesses
may trigger this proximal cause through a variety of
different causal pathways. While this is an open ques-
tion, it would have been desirable to exclude subjects
with known organic causes of fatigue from our analysis,
since at best, this would have resulted in a more
homogeneous group of neurasthenics. However, we
could not exclude organically-caused fatigue because
no physical examination to objectively ascertain or-
ganic causes had been carried out. Only participants’
subjective causal attributions were available, but these
cannot in general be taken to reflect true somatic cau-
ses, and thus are not a reliable basis for exclusions.
Analysing the associations between 3-months
neurasthenia and depression one has to be aware that
MDE requires a minimum duration of only 2 weeks.
This large time difference reduces comparability and
may explain some controversional findings. Sample
sizes were partly small, and might also account for
some of the inconsistencies. They may limit the gen-
eralizability of our findings to the general population
or to patient populations. The empirical and con-
ceptual overlap between neurasthenia and depression
confounds the issue of diagnostic stability, but this
limitation is inherent and unavoidable.
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